The Chronic Kidney Disease Diagnosis and Evaluation process uses simple blood, urine, and imaging tests to check a child’s kidney health. Early detection is key.
Send us all your questions or requests, and our expert team will assist you.
Diagnosing kidney disease requires a comprehensive approach that goes beyond simple symptom-checking. Because the condition is often silent in its early stages, laboratory testing is the only way to detect functional decline before significant damage occurs. The evaluation aims to determine kidney function, identify the underlying cause, and assess the rate of progression.
Clinicians utilize a combination of blood tests, urine analysis, and imaging studies to build a complete picture of renal health. This multimodal approach ensures that reversible causes are identified and that chronic conditions are staged accurately to guide treatment.
The eGFR is the primary blood test used to check kidney function. It estimates the amount of blood that passes through the glomeruli each minute. The calculation is based on the level of creatinine in the blood, along with factors like age, sex, and body type.
Creatinine is a waste product from the typical breakdown of muscle tissue. Healthy kidneys filter creatinine out of the blood. When kidney function slows down, creatinine levels rise. The eGFR translates this creatinine level into a functional score.
An eGFR of 90 or higher is considered normal. A result below 60 for three months or more indicates chronic kidney disease. A result below 15 indicates kidney failure. Tracking eGFR over time allows doctors to monitor kidney function stability or decline.
It is important to note that eGFR is an estimate. Extreme muscle mass, unusual diets, or certain medications can affect creatinine levels, potentially skewing the result. In such cases, other markers, such as Cystatin C, may be used for verification.
Urine tests reveal how the kidneys are handling waste and whether the filtration barrier is intact—a standard urinalysis checks for blood, infection, and protein. However, more specific tests are needed to quantify the damage.
The Urine Albumin to Creatinine Ratio (uACR) is the gold standard for detecting protein leakage. Albumin is a protein that should remain in the blood. Its presence in the urine, known as albuminuria, is often the earliest sign of kidney disease, particularly in diabetes.
Microalbuminuria (small amounts of protein) indicates early damage and increased cardiovascular risk. Macroalbuminuria (large amounts) indicates advanced damage. Monitoring uACR helps evaluate the effectiveness of treatments designed to protect the kidney.
A 24-hour urine collection may be requested for a more precise measurement of kidney function and protein loss. This involves collecting all urine produced in a day to calculate the exact clearance rate of creatinine and protein.
Ultrasound is the first-line imaging modality for evaluating the kidneys. It uses sound waves to create images of the kidney’s size, shape, and structure without exposing the patient to radiation or contrast dyes, which can be harmful to compromised kidneys.
Ultrasound can detect structural abnormalities, such as cysts (indicative of PKD), tumors, or kidney stones. It can also reveal whether the kidneys are small and shrunken, suggesting long-standing chronic disease, or normal in size, which might indicate an acute issue.
The test can also assess the echogenicity, or brightness, of kidney tissue. Increased echogenicity often correlates with scarring and fibrosis. Doppler ultrasound can be added to evaluate blood flow in the renal arteries and veins and to check for stenosis or blockages.
This imaging provides the anatomical context for the biochemical abnormalities found in blood and urine tests. It is essential to rule out reversible causes of kidney failure, such as urinary tract obstruction.
Advanced imaging, such as CT scans or MRI, may be used when ultrasound does not provide enough detail. These scans offer high-resolution cross-sectional images, helpful in identifying complex masses, stones, or vascular anatomy.
However, caution is required. CT scans usually use iodinated contrast dye, which can cause further kidney damage (contrast-induced nephropathy) in patients with reduced function. MRI contrast agents (gadolinium) have been linked to a rare but serious condition called Nephrogenic Systemic Fibrosis in patients with advanced kidney disease.
Protocols for these scans are often modified for kidney patients, using low-dose protocols or avoiding contrast altogether. They are typically reserved for specific diagnostic questions that ultrasound cannot answer, such as tumor staging or surgical planning.
These modalities are also crucial for evaluating the renal vasculature before interventions such as stenting for renal artery stenosis. They provide a roadmap of the kidney’s plumbing and blood supply.
A kidney biopsy is the most definitive diagnostic tool. It involves taking a small sample of kidney tissue using a thin needle, usually guided by ultrasound. This tissue is then examined under a microscope by a pathologist.
Biopsies are not performed on everyone. They are reserved for cases where the cause of kidney disease is unclear, the disease is progressing rapidly, or there is suspicion of a systemic disease such as lupus or vasculitis affecting the kidneys.
The biopsy can distinguish between different types of glomerulonephritis and determine the extent of scarring. This information is vital for prognosis and for deciding whether aggressive treatments such as immunosuppressants are warranted or whether the damage is irreversible.
It helps differentiate between active inflammation (which can be treated) and chronic fibrosis (which cannot). This distinction prevents patients from being exposed to the risks of strong medications that would not benefit them.
Since hypertension is both a cause and a consequence of kidney disease, rigorous blood pressure evaluation is part of the diagnostic workup. This may involve ambulatory blood pressure monitoring to assess control over a 24-hour period.
Cardiovascular health is assessed using ECGs and echocardiograms. Kidney disease significantly increases the risk of heart attacks and heart failure. Evaluating the heart helps clinicians effectively manage cardiorenal syndrome.
Lipid profiles are also checked, as dyslipidemia is common in CKD and contributes to vascular damage. Managing heart health is an integral part of diagnosing and treating the renal patient.
Send us all your questions or requests, and our expert team will assist you.
The procedure is done with a local anesthetic to numb the skin and the area around the kidney. You may feel pressure or a dull ache during the procedure, but it should not be sharp pain. Afterwards, the area may be sore for a few days, similar to a bruise.
If you have risk factors like diabetes or high blood pressure, you should have your eGFR and urine albumin checked at least once a year. If you have diagnosed with CKD, your doctor may recommend testing every 3 to 6 months, depending on the stage.
Yes, dehydration can temporarily raise your creatinine levels and lower your eGFR, making your kidney function look worse than it is. It can also concentrate your urine, which can affect protein measurements. It is essential to be well hydrated for accurate tests.
Normal creatinine levels typically range from 0.6 to 1.2 mg/dL for men and 0.5 to 1.1 mg/dL for women. However, “normal” depends on your muscle mass and age. A very muscular person might have higher levels naturally, while an older adult might have lower levels despite kidney issues.
A spot urine check gives a snapshot, but protein excretion can vary throughout the day. A 24-hour collection offers the total amount of protein lost and the exact clearance rate of creatinine, providing the most accurate measurement of kidney filtration function.
Your Comparison List (you must select at least 2 packages)
